Julius Popp1, Aikaterini Oikonomidi2, Domilė Tautvydaitė2, Loïc Dayon3, Michael Bacher4, Eugenia Migliavacca3, Hugues Henry5, Richard Kirkland6, India Severin3, Jérôme Wojcik7, Gene L Bowman3. 1. CHUV, Old Age Psychiatry, Department of Psychiatry, Lausanne, Switzerland. Electronic address: Julius.Popp@chuv.ch. 2. CHUV, Old Age Psychiatry, Department of Psychiatry, Lausanne, Switzerland. 3. Nestlé Institute of Health Sciences, EPFL Campus, Lausanne, Switzerland. 4. Philipps University of Marburg, Institute of Immunology, Marburg, Germany. 5. CHUV, Department of Laboratories, Lausanne, Switzerland. 6. Prometheus Laboratories, San Diego, USA. 7. Quartz Bio, Geneva, Switzerland.
Abstract
BACKGROUND: In vitro and animal studies have linked neuroinflammation to Alzheimer's disease (AD) pathology. Studies on markers of inflammation in subjects with mild cognitive impairment or AD dementia provided inconsistent results. We hypothesized that distinct blood and cerebrospinal fluid (CSF) inflammatory markers are associated with biomarkers of amyloid and tau pathology in older adults without cognitive impairment or with beginning cognitive decline. OBJECTIVE: To identify blood-based and CSF neuroinflammation marker signatures associated with AD pathology (i.e. an AD CSF biomarker profile) and to investigate associations of inflammation markers with CSF biomarkers of amyloid, tau pathology, and neuronal injury. DESIGN/ METHODS: Cross-sectional analysis was performed on data from 120 older community-dwelling adults with normal cognition (n=48) or with cognitive impairment (n=72). CSF Aβ1-42, tau and p-tau181, and a panel of 37 neuroinflammatory markers in both CSF and serum were quantified. Least absolute shrinkage and selection operator (LASSO) regression was applied to determine a reference model that best predicts an AD CSF biomarker profile defined a priori as p-tau181/Aβ1-42 ratio >0.0779. It was then compared to a second model that included the inflammatory markers from either serum or CSF. In addition, the correlations between inflammatory markers and CSF Aβ1-42, tau and p-tau181 levels were assessed. RESULTS: Forty-two subjects met criteria for having an AD CSF biomarker profile. The best predictive models included 8 serum or 3 CSF neuroinflammatory markers related to cytokine mediated inflammation, vascular injury, and angiogenesis. Both models improved the accuracy to predict an AD biomarker profile when compared to the reference model. In analyses separately performed in the subgroup of participants with cognitive impairment, adding the serum or the CSF neuroinflammation markers also improved the accuracy of the diagnosis of AD pathology. None of the inflammatory markers correlated with the CSF Aβ1-42 levels. Six CSF markers (IL-15, MCP-1, VEGFR-1, sICAM1, sVCAM-1, and VEGF-D) correlated with the CSF tau and p-tau181 levels, and these associations remained significant after controlling for age, sex, cognitive impairment, and APOEε4 status. CONCLUSIONS: The identified serum and CSF neuroinflammation biomarker signatures improve the accuracy of classification for AD pathology in older adults. Our results suggest that inflammation, vascular injury, and angiogenesis as reflected by CSF markers are closely related to cerebral tau pathology.
BACKGROUND: In vitro and animal studies have linked neuroinflammation to Alzheimer's disease (AD) pathology. Studies on markers of inflammation in subjects with mild cognitive impairment or AD dementia provided inconsistent results. We hypothesized that distinct blood and cerebrospinal fluid (CSF) inflammatory markers are associated with biomarkers of amyloid and tau pathology in older adults without cognitive impairment or with beginning cognitive decline. OBJECTIVE: To identify blood-based and CSF neuroinflammation marker signatures associated with AD pathology (i.e. an AD CSF biomarker profile) and to investigate associations of inflammation markers with CSF biomarkers of amyloid, tau pathology, and neuronal injury. DESIGN/ METHODS: Cross-sectional analysis was performed on data from 120 older community-dwelling adults with normal cognition (n=48) or with cognitive impairment (n=72). CSF Aβ1-42, tau and p-tau181, and a panel of 37 neuroinflammatory markers in both CSF and serum were quantified. Least absolute shrinkage and selection operator (LASSO) regression was applied to determine a reference model that best predicts an AD CSF biomarker profile defined a priori as p-tau181/Aβ1-42 ratio >0.0779. It was then compared to a second model that included the inflammatory markers from either serum or CSF. In addition, the correlations between inflammatory markers and CSF Aβ1-42, tau and p-tau181 levels were assessed. RESULTS: Forty-two subjects met criteria for having an AD CSF biomarker profile. The best predictive models included 8 serum or 3 CSF neuroinflammatory markers related to cytokine mediated inflammation, vascular injury, and angiogenesis. Both models improved the accuracy to predict an AD biomarker profile when compared to the reference model. In analyses separately performed in the subgroup of participants with cognitive impairment, adding the serum or the CSF neuroinflammation markers also improved the accuracy of the diagnosis of AD pathology. None of the inflammatory markers correlated with the CSF Aβ1-42 levels. Six CSF markers (IL-15, MCP-1, VEGFR-1, sICAM1, sVCAM-1, and VEGF-D) correlated with the CSF tau and p-tau181 levels, and these associations remained significant after controlling for age, sex, cognitive impairment, and APOEε4 status. CONCLUSIONS: The identified serum and CSF neuroinflammation biomarker signatures improve the accuracy of classification for AD pathology in older adults. Our results suggest that inflammation, vascular injury, and angiogenesis as reflected by CSF markers are closely related to cerebral tau pathology.
Authors: Keenan A Walker; B Gwen Windham; Charles H Brown; David S Knopman; Clifford R Jack; Thomas H Mosley; Elizabeth Selvin; Dean F Wong; Timothy M Hughes; Yun Zhou; Alden L Gross; Rebecca F Gottesman Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: T N C Magalhães; M Weiler; C V L Teixeira; T Hayata; A S Moraes; V O Boldrini; L M Dos Santos; B M de Campos; T J R de Rezende; H P G Joaquim; L L Talib; O V Forlenza; F Cendes; Marcio L F Balthazar Journal: Mol Neurobiol Date: 2017-10-16 Impact factor: 5.590
Authors: Giselli Scaini; Tássia Tonon; Carolina F Moura de Souza; Patricia F Schuck; Gustavo C Ferreira; João Quevedo; João Seda Neto; Tatiana Amorim; Jose S Camelo; Ana Vitoria Barban Margutti; Rafael Hencke Tresbach; Fernanda Sperb-Ludwig; Raquel Boy; Paula F V de Medeiros; Ida Vanessa D Schwartz; Emilio Luiz Streck Journal: J Inherit Metab Dis Date: 2018-05-08 Impact factor: 4.982
Authors: Bianca A Trombetta; Becky C Carlyle; Aaron M Koenig; Leslie M Shaw; John Q Trojanowski; David A Wolk; Joseph J Locascio; Steven E Arnold Journal: PLoS One Date: 2018-03-05 Impact factor: 3.240